METTL3 and acute myeloid leukemia: Similarly, WD6305, a potent and selective PROTAC, effectively degrades the METTL3‐METTL14 complex, suppressing m6A methylation and enhancing apoptosis in AML cells beyond its parent inhibitor's capacity.[162] However, while promising, their clinical application faces significant challenges.